Industry Newsdupilumaballergic fungal rhinosinusitisphase 3u.s. approval
Dupixent Receives U.S. Approval For AFRS
|
5.6
The U.S. approved Dupixent (dupilumab) as the first and only treatment for allergic fungal rhinosinusitis (AFRS). Approval in adults and children aged 6 years and older is supported by a Phase 3 trial showing significant reductions in nasal signs and symptoms.
Scoring Rationale
Clinical approval significance drives score, but niche scope and RSS-only limited source reduce impact despite Phase 3 support.
Practice interview problems based on real data
1,500+ SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
